NCT06331650View on ClinicalTrials.gov

A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 9, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

October 31, 2025

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

cadonilimab

Cardunnilizumab: the recommended dose is 10mg/kg every 3 weeks on the first day of each cycle; Discontinuation of the drug may be considered if intolerable adverse reactions occur.

Trial Locations (1)

510000

RECRUITING

The First Affiliated Hospital of Guangzhou Medical University, Guangdong

All Listed Sponsors
lead

Guangzhou Institute of Respiratory Disease

OTHER